CHANGE IN KDIGO KIDNEY RISK CATEGORY WITH SEMAGLUTIDE TREATMENT-A POST HOC ANALYSIS OF THE SUSTAIN 6 TRIAL

被引：0
|
作者：
Tuttle, Katherine [1 ]
Bain, Stephen C. [2 ]
Cherney, David [3 ]
Lawson, Jack [4 ]
Rasmussen, Soren [4 ]
Vrhnjak, Blaz [4 ]
Khunti, Kamlesh [5 ]
机构：
[1] Univ WA Providence Hlth, Spokane, WA 99258 USA
[2] Swansea Univ, Med Sch, Swansea, W Glam, Wales
[3] Univ Toronto, Univ Hlth Network, Toronto, ON, Canada
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Leicester, Leics, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2022年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
MO462
引用
收藏
页码：I331 / I331
页数：1
相关论文
共 50 条
  • [31] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [32] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S130 - S131
  • [33] Effects of liraglutide and semaglutide on stroke subtypes in patients with type 2 diabetes: a post hoc analysis of the LEADER, SUSTAIN 6 and PIONEER 6 trials
    Strain, W. D.
    Holst, A. G.
    Rasmussen, S.
    Saevereid, H. A.
    James, M. A.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2424 - 2424
  • [34] Effect of semaglutide versus placebo on cardiovascular outcomes by baseline HbA1c: SUSTAIN 6 and PIONEER 6 post hoc analysis
    Mellbin, L. G.
    Bhatt, D. L.
    David, J. -P.
    Petrie, M. C.
    Rasmussen, S.
    Schytz, P. A.
    Vilsboll, T.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S304 - S305
  • [35] Physical Function of RA patients Tapering Treatment-A Post Hoc Analysis of the Randomized Controlled RETRO Trial
    Stephan, Marlene
    Tascilar, Koray
    Yalcin-Mutlu, Melek
    Hagen, Melanie
    Haschka, Judith
    Reiser, Michaela
    Hartmann, Fabian
    Kleyer, Arnd
    Hueber, Axel J.
    Manger, Bernhard
    Figueiredo, Camille
    Cobra, Jayme Fogagnolo
    Tony, Hans-Peter
    Finzel, Stephanie
    Kleinert, Stefan
    Wendler, Joerg
    Schuch, Florian
    Ronneberger, Monika
    Feuchtenberger, Martin
    Fleck, Martin
    Manger, Karin
    Ochs, Wolfgang
    Schmitt-Haendle, Matthias
    Lorenz, Hannes Martin
    Nuesslein, Hubert
    Alten, Rieke
    Henes, Joerg
    Krueger, Klaus
    Schett, Georg
    Rech, Juergen
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [36] Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials
    DeSouza, Cyrus
    Cariou, Bertrand
    Garg, Satish
    Lausvig, Nanna
    Navarria, Andrea
    Fonseca, Vivian
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (02): : 543 - 556
  • [37] Consistent Kidney Benefits With Semaglutide vs. Placebo Regardless of Baseline Urine Albumin Creatinine Ratio in Subjects With Type 2 Diabetes at High Cardiovascular Risk: A Post Hoc Analysis of SUSTAIN 6
    Heerspink, Hiddo J. L.
    Kuhlman, Anja B.
    Mann, Johannes F.
    Rasmussen, Soren
    Rossing, Peter
    Vrhnjak, Blaz
    Cherney, David
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 676 - 676
  • [38] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [39] Semaglutide consistently reduces cardiovascular risk in patients with type 2 diabetes regardless of baseline cardiovascular risk level: post hoc analyses of the SUSTAIN trial programme
    Bain, S.
    Rea, R.
    Warren, M.
    Holst, A. G.
    Vrazic, H.
    Madsbad, S.
    EUROPEAN HEART JOURNAL, 2018, 39 : 598 - 598
  • [40] Semaglutide reduces hsCRP levels across different treatment settings: post hoc analyses of SUSTAIN and PIONEER trials
    Mosenzon, O.
    Capehorn, M.
    De Remigis, A.
    Rasmussen, S.
    Weimers, P.
    Rosenstock, J.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 95 - 96
12345